Moxifloxacin in the treatment of community-acquired pneumonia in adults: what's new?
https://doi.org/10.21518/2079-701X-2014-16-36-43
Abstract
The article is devoted to the role of respiratory fluoroquinolones in the treatment of community-acquired pneumonia. Respiratory fluoroquinolones are key in the treatment of the disease as they affect virtually all pathogens of community-acquired pneumonia, and have attractive pharmacokinetic and pharmacodynamic profiles. The article tells about the results of several multicenter clinical trials of moxifloxacin and its use as a second-line therapy in tuberculosis of the respiratory tract.
Keywords
пневмония,
туберкулез,
фторхинолоны,
моксифлоксацин,
pneumonia,
tuberculosis,
fluoroquinolones,
ofloxacin
About the Author
A. I. Sinopalnikov
Russian Medical Academy of Postgraduate Education, Moscow
Russian Federation
Russian Federation
References
1. Naber K, Adam D. Expertengruppe der PEG. Einteilung der Fluorchinolone. Chemother],, 1998, 7: 66-68.
2. Bolon MK. The newer fluoroquinolones. Med Clin NAmer., 2011, 95: 793-817.
3. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America and American Thoracic Society Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis, 2007, 44(Suppl 2): 27-72.
4. Woodhead M, Blasi F, Ewig S and the ERS/ESCMID Task Force. Guidelines for the management of adult lower respiratory tract infections. Clin Microbiol Infect, 2011, 17 (Suppl. 6): 1-59.
5. Чучалин А.Г, Синопальников А.И., Козлов Р.С. и соавт. Внебольничная пневмония у взрослых. Практические рекомендации по диагностике, лечению и профилактике. Клин, микробиол. и антимикроб. химиотер, 2010, 12(3): 186-226.
6. Nair GB, Niederman MS. Community-acquired pneumonia: an unfinished battle. Med Clin N Amer 2011, 95: 1143-1161.
7. Soman A, Honeybourne D, Andrews J et al. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. ] Antimicrob Cmemother 1999, 44: 835-838.
8. Blondeau JM, Laskowski R, Bjarnason J et al. Comparative in vitro activity of gatifloxacin, grapafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int ] Antimicrob Agents, 2000, 14: 45-50.
9. Leroy O, Santre C, Beuscart C et al. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med 1995, 21: 24-31.
10. Vardakas KZ, Siempos II, Grammatikos A et al. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. Can Med Assoc]., 2008, 179: 1269-1277.
11. Finch R, Schurmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother, 2002, 46: 1746-1754.
12. Fogarty CM, Grossman C, Williams J, et al. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia. Infect Med, 1999, 16: 748-763.
13. Peptipretz P, Arvis P, Marel M, et al. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate community-acquired, suspected pneumococcal pneumonia in adults. Chest, 2001, 119: 185-195.
14. Torres A, Muir JF, Corris P, et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. EurRespir], 2003, 21: 153-143.
15. Finch R, Schurmann D, Collins O, et al. Randomized controlled trial of sequential intravenous and oral moxifloxacin compared with sequential intravenous and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother, 2002, 46: 1746-1754.
16. Katz E, Larsen IS, Fogarty CM, et al. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. ]EmergMed, 2004, 27: 395-405.
17. Welte T, Petermann W, Schuermann D, et al. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis 2005; 41: 1697-1705.
18. Anzueto A, Niederman MS, Pearle J, et al. Community-acquired pneumonia in the elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 2006; 42: 73-81.
Review
For citations:
Sinopalnikov AI. Moxifloxacin in the treatment of community-acquired pneumonia in adults: what's new? Meditsinskiy sovet = Medical Council. 2014;(16):36-43. (In Russ.) https://doi.org/10.21518/2079-701X-2014-16-36-43
Views:
402
Email this article 